Sobering realities of surviving Hodgkin lymphoma

Abstract

In this issue of Blood, Castellino and colleagues investigate morbidity and mortality in a cohort of long-term survivors of Hodgkin lymphoma (HL) from the Childhood Cancer Survivor Study. They observe frequent and serious late sequelae of therapy occurring even after 20 years of follow-up; their findings highlight the need to consider long-term implications when selecting therapeutic strategies for young patients with curable lymphomas.